Cytokine Signalling Forum

Publications





June 17

Resultados (outcomes) de La Inhibición cíclica del Factor de Necrosis Tumoral versus Cambiar para un fármaco modificador de enfermedad con un nuevo mecanismo de acción

Chastek B, Becker LK, Chen CI, Mahajan P and Curtis JR.
J Med Econ 2017;20:464–73

This retrospective study looked at claims-based datasets to establish whether it is preferable to switch to another TNF inhibitor (TNFi) or to a therapy with a different mechanism of action (MOA) when RA treatment failure occurs with an initial TNFi, due to inadequate response or lack of tolerability. Administrative claims data from a large US database were used to compare treatment patterns, treatment effectiveness (based on fulfillment of six criteria) and costs in in the 12 months after RA p...

Keywords: JAK, Tofacitinib, Real World, Value

Translated by: Igor Kos